XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.2
The Company (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 29, 2020
Apr. 29, 2020
Aug. 23, 2018
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Apr. 20, 2017
Aug. 31, 2015
Long-term debt                
Retained earnings (accumulated deficit)       $ (1,554,523) $ (1,554,523) $ (1,190,499)    
Rights Exchange Agreement                
Long-term debt                
Shares to issue under Rights Exchange Agreement   2,821,176   2,821,176 2,821,176      
Cash consideration payment under Rights Exchange Agreement   $ 36,900            
Convertible debt | 1.50% Convertible senior notes due 2026                
Long-term debt                
Interest rate ( as a percent )       1.50% 1.50% 1.50%    
Convertible debt | 3.00% Convertible senior notes due 2022                
Long-term debt                
Interest rate ( as a percent )               3.00%
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC                
Long-term debt                
Development milestone payments which the entity is obligated to pay             $ 50,000  
Agilis                
Long-term debt                
Cash consideration     $ 49,200          
Equity Interest Issued, number of shares (in shares)     3,500,907          
Numerator for calculation of number of shares of equity interests issued to acquire entity     $ 150,000          
Trading day period     10 days          
Development milestone payments which the entity is obligated to pay   40,000   $ 40,000 $ 40,000      
Development milestone payment obligations, net of cancellation and forfeiture         $ 20,000      
Milestone obligation payments made       $ 2,400        
Net sales amount   150,000            
Agilis | Minimum                
Long-term debt                
Development milestone payments which the entity is obligated to pay $ 37,600 $ 37,600            
Product sales   2.00%   2.00% 2.00%      
Agilis | Maximum                
Long-term debt                
Development milestone payments which the entity is obligated to pay 40,000     $ 60,000 $ 60,000      
Priority review voucher amount         535,000      
Net sales amount       $ 150,000 $ 150,000      
Product sales   6.00%   6.00% 6.00%      
Agilis | Rights Exchange Agreement                
Long-term debt                
Contingent liability, cancellation and forfeiture $ 211,600 $ 211,600            
Priority review voucher amount   174,000            
Development milestone payment obligations, net of cancellation and forfeiture   20,000            
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture   $ 361,000            
Agilis | Rights Exchange Agreement | Maximum                
Long-term debt                
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture         $ 361,000      
Agilis | Non-collaborative Arrangement Transactions                
Long-term debt                
Development milestone payments which the entity is obligated to pay       $ 40,000 $ 40,000